SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alok S. Tripathi, Paresh J. Wadhwani, Papiya M. Majumder, Anil V. Chandewar, Shirish Marathe, Pratik G. Mahajan, Amylin dual action: a second gluco regulatory β-cell hormone, treatment and cause for the diabetes, International Journal of Diabetes in Developing Countries, 2014,

    CrossRef

  2. 2
    Ping Cao, Andisheh Abedini, Daniel P Raleigh, Aggregation of islet amyloid polypeptide: from physical chemistry to cell biology, Current Opinion in Structural Biology, 2013, 23, 1, 82

    CrossRef

  3. 3
    Karen Pillay, Patrick Govender, Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes, BioMed Research International, 2013, 2013, 1

    CrossRef

  4. 4
    Sarah D. Corathers, Shawn Peavie, Marzieh Salehi, Complications of Diabetes Therapy, Endocrinology and Metabolism Clinics of North America, 2013, 42, 4, 947

    CrossRef

  5. 5
    Chi-cheng Chiu, Sadanand Singh, Juan J. de Pablo, Effect of Proline Mutations on the Monomer Conformations of Amylin, Biophysical Journal, 2013, 105, 5, 1227

    CrossRef

  6. 6
    P. Cao, A. Abedini, H. Wang, L.-H. Tu, X. Zhang, A. M. Schmidt, D. P. Raleigh, Islet amyloid polypeptide toxicity and membrane interactions, Proceedings of the National Academy of Sciences, 2013, 110, 48, 19279

    CrossRef

  7. 7
    Ping Cao, Peter Marek, Harris Noor, Vadim Patsalo, Ling-Hsien Tu, Hui Wang, Andisheh Abedini, Daniel P. Raleigh, Islet amyloid: From fundamental biophysics to mechanisms of cytotoxicity, FEBS Letters, 2013, 587, 8, 1106

    CrossRef

  8. 8
    Andisheh Abedini, Ann Marie Schmidt, Mechanisms of islet amyloidosis toxicity in type 2 diabetes, FEBS Letters, 2013, 587, 8, 1119

    CrossRef

  9. 9
    Eugenio Angueira, Non-Insulin Treatments for Diabetes, American Journal of Therapeutics, 2013, 20, 4, 377

    CrossRef

  10. You have free access to this content10
    George Grunberger, Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine-QR (2型糖尿病治疗新药:第1部分.普兰林肽与溴隐亭-QR), Journal of Diabetes, 2013, 5, 2
  11. You have free access to this content11
    Lewis Landsberg, Louis J. Aronne, Lawrence J. Beilin, Valerie Burke, Leon I. Igel, Donald Lloyd-Jones, James Sowers, Obesity-Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment, The Journal of Clinical Hypertension, 2013, 15, 1
  12. 12
    Lewis Landsberg, Louis J. Aronne, Lawrence J. Beilin, Valerie Burke, Leon I. Igel, Donald Lloyd-Jones, James Sowers, Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension, Obesity, 2013, 21, 1
  13. 13
    P. George, R. J. McCrimmon, Potential role of non-insulin adjunct therapy in Type 1 diabetes, Diabetic Medicine, 2013, 30, 2
  14. 14
    Margaret C. Lo, M. Cecilia Lansang, Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus, American Journal of Therapeutics, 2013, 20, 6, 638

    CrossRef

  15. 15
    Leon I. Igel, Amanda G. Powell, Caroline M. Apovian, Louis J. Aronne, Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus, Current Atherosclerosis Reports, 2012, 14, 1, 60

    CrossRef

  16. 16
    Andrew A. Young, Brainstem sensing of meal-related signals in energy homeostasis, Neuropharmacology, 2012, 63, 1, 31

    CrossRef

  17. 17
    Adarsh K. Gupta, Diabetes obesity link: how to lower your risk of diabetes with weight management, Osteopathic Family Physician, 2012, 4, 5, 149

    CrossRef

  18. 18
    Harold E Lebovitz, Pramlintide: profile of an amylin analog, Expert Review of Endocrinology & Metabolism, 2012, 7, 6, 599

    CrossRef

  19. 19
    Janice D. Wagner, Jennifer A. Cann, Li Zhang, H. James Harwood, Nonhuman Primates in Biomedical Research, 2012,

    CrossRef

  20. 20
    Yehuda Handelsman, Jeffrey I. Mechanick, Lawrence Blonde, George Grunberger, Zachary T. Bloomgarden, George A. Bray, Samuel Dagogo-Jack, Jaime A. Davidson, Daniel Einhorn, Om Ganda, Alan J. Garber, Irl B. Hirsch, Edward S. Horton, Faramarz Ismail-Beigi, Paul S. Jellinger, Kenneth L. Jones, Lois Jovanovič, Harold Lebovitz, Philip Levy, Etie S. Moghissi, Eric A. Orzeck, Aaron I. Vinik, Kathleen L. Wyne, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan, Endocrine Practice, 2011, 17, s2, 1

    CrossRef

  21. 21
    G. Nicholson, G. M. Hall, Diabetes mellitus: new drugs for a new epidemic, British Journal of Anaesthesia, 2011, 107, 1, 65

    CrossRef

  22. 22
    George A. Bray, Medications for Weight Reduction, Medical Clinics of North America, 2011, 95, 5, 989

    CrossRef

  23. 23
    Charmaine S Tam, Virgile Lecoultre, Eric Ravussin, Novel strategy for the use of leptin for obesity therapy, Expert Opinion on Biological Therapy, 2011, 11, 12, 1677

    CrossRef

  24. 24
    Wiebke Fenske, Jennifer Parker, Stephen R Bloom, Pharmacotherapy for obesity: a field in crisis?, Expert Review of Endocrinology & Metabolism, 2011, 6, 4, 563

    CrossRef

  25. 25
    Lisa M Younk, Maia Mikeladze, Stephen N Davis, Pramlintide and the treatment of diabetes: a review of the data since its introduction, Expert Opinion on Pharmacotherapy, 2011, 12, 9, 1439

    CrossRef

  26. 26
    Mariela Glandt, Itamar Raz, Present and Future: Pharmacologic Treatment of Obesity, Journal of Obesity, 2011, 2011, 1

    CrossRef

  27. 27
    A Guide to Obesity and the Metabolic Syndrome, 2011,

    CrossRef

  28. 28
    Harold E. Lebovitz, Adjunct therapy for type 1 diabetes mellitus, Nature Reviews Endocrinology, 2010, 6, 6, 326

    CrossRef

  29. 29
    Allen Lee, Braden Kuo, Metoclopramide in the treatment of diabetic gastroparesis, Expert Review of Endocrinology & Metabolism, 2010, 5, 5, 653

    CrossRef

  30. 30
    Thomas D Aicher, Steven A Boyd, Maralee McVean, Anthony Celeste, Novel therapeutics and targets for the treatment of diabetes, Expert Review of Clinical Pharmacology, 2010, 3, 2, 209

    CrossRef

  31. 31
    Mark Peyrot, Richard R. Rubin, William H. Polonsky, H. Jennie, Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs, Current Medical Research and Opinion, 2010, 26, 5, 1047

    CrossRef

  32. 32
    George A. Bray, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  33. 33
    Kishore M Gadde, David B Allison, Combination therapy for obesity and metabolic disease, Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 5, 353

    CrossRef

  34. 34
    David M. Huffman, George W. McLean, Maighan A. Seagrove, Continuous Subcutaneous Pramlintide Infusion Therapy in Patients with Type 1 Diabetes: Observations from a Pilot Study, Endocrine Practice, 2009, 15, 7, 689

    CrossRef

  35. 35
    Jennifer Sherr, Eda Cengiz, William V. Tamborlane, From pumps to prevention: recent advances in the treatment of type 1 diabetes, Drug Discovery Today, 2009, 14, 19-20, 973

    CrossRef

  36. 36
    George A. Bray, Medications for Obesity: Mechanisms and Applications, Clinics in Chest Medicine, 2009, 30, 3, 525

    CrossRef

  37. 37
    Allen B. King, Minimal Reduction in Insulin Dosage with Pramlintide Therapy when Pretreatment Near-Normal Glycemia is Established and Square-Wave Meal Bolus is Used, Endocrine Practice, 2009, 15, 3, 229

    CrossRef

  38. 38
    Vandana S Raman, Rubina A Heptulla, New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus, Pediatric Research, 2009, 65, 4, 370

    CrossRef

  39. You have free access to this content39
    Benjamin C. T. Field, Owais B. Chaudhri, Stephen R. Bloom, Obesity treatment: novel peripheral targets, British Journal of Clinical Pharmacology, 2009, 68, 6
  40. 40
    H. Peter Chase, Karen Lutz, Richard Pencek, Bei Zhang, Lisa Porter, Pramlintide Lowered Glucose Excursions and Was Well-Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized, Single-Blind, Placebo-Controlled, Crossover Study, The Journal of Pediatrics, 2009, 155, 3, 369

    CrossRef

  41. 41
    Lalita Khaodhiar, Sue Cummings, Caroline M. Apovian, Treating diabetes and prediabetes by focusing on obesity management, Current Diabetes Reports, 2009, 9, 5, 348

    CrossRef

  42. 42
    Mark Peyrot, Richard R. Rubin, William H. Polonsky, Diabetes Distress and Its Association with Clinical Outcomes in Patients with Type 2 Diabetes Treated with Pramlintide as an Adjunct to Insulin Therapy, Diabetes Technology & Therapeutics, 2008, 10, 6, 461

    CrossRef

  43. 43
    D. Maggs, I. MacDonald, M. A. Nauck, Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes, Diabetes, Obesity and Metabolism, 2008, 10, 1
  44. 44
    Benjamin C T Field, Alison M Wren, Dunstan Cooke, Stephen R Bloom, Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity, Drugs, 2008, 68, 2, 147

    CrossRef

  45. 45
    Nicole C Kesty, Jonathan D Roth, David Maggs, Hormone-based therapies in the regulation of fuel metabolism and body weight, Expert Opinion on Biological Therapy, 2008, 8, 11, 1733

    CrossRef

  46. 46
    George A. Bray, Medications for Weight Reduction, Endocrinology and Metabolism Clinics of North America, 2008, 37, 4, 923

    CrossRef

  47. 47
    H.E. Lebovitz, New treatments of diabetes: The β-amylin agonists, Annales d'Endocrinologie, 2008, 69, 2, 147

    CrossRef

  48. 48
    Mellisa A. Hall, TYPE 2 DIABETES, Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional, 2008, 26, 6, 346

    CrossRef

  49. 49
    JAY S. SKYLER, Levin and O'Neal's The Diabetic Foot, 2008,

    CrossRef

  50. 50
    Helena W. Rodbard, Lawrence Blonde, Susan S. Braithwaite, Elise M. Brett, Rhoda H. Cobin, Yehuda Handelsman, Richard Hellman, Paul S. Jellinger, Lois G. Jovanovic, Philip Levy, Jeffrey I. Mechanick, Farhad Zangeneh, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus, Endocrine Practice, 2007, 13, s1, 1

    CrossRef

  51. 51
    Richard R. Rubin, Mark Peyrot, Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy, Current Medical Research and Opinion, 2007, 23, 8, 1919

    CrossRef

  52. 52
    Michael Camilleri, Diabetic Gastroparesis, New England Journal of Medicine, 2007, 356, 8, 820

    CrossRef

  53. 53
    David Russell-Jones, Rehman Khan, Insulin-associated weight gain in diabetes – causes, effects and coping strategies, Diabetes, Obesity and Metabolism, 2007, 9, 6
  54. 54
    George A. Bray, Medical Therapy for Obesity—Current Status and Future Hopes, Medical Clinics of North America, 2007, 91, 6, 1225

    CrossRef

  55. 55
    Brigitte L. Sicat, Laura A. Morgan, New Therapeutic Options for the Management of Diabetes, The Consultant Pharmacist, 2007, 22, 1, 45

    CrossRef

  56. 56
    Dina E. Green, New Therapies for Diabetes, Clinical Cornerstone, 2007, 8, 2, 58

    CrossRef

  57. 57
    Wendy M Miller, Katherine E Nori Janosz, Kerstyn C Zalesin, Peter A McCullough, Nutraceutical meal replacements: more effective than all-food diets in the treatment of obesity, Therapy, 2007, 4, 5, 623

    CrossRef

  58. 58
    Steven V Edelman, Brock E Schroeder, Juan P Frias, Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus, Expert Review of Endocrinology & Metabolism, 2007, 2, 1, 9

    CrossRef

  59. 59
    Devada Singh-Franco, Gisela Robles, David Gazze, Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus, Clinical Therapeutics, 2007, 29, 4, 535

    CrossRef

  60. 60
    Diane Karl, Athena Philis-Tsimikas, Tamara Darsow, Gayle Lorenzi, Terrie Kellmeyer, Karen Lutz, Yan Wang, Juan P. Frias, Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight, Diabetes Technology & Therapeutics, 2007, 9, 2, 191

    CrossRef

  61. 61
    Paul S. Jellinger, Jaime A. Davidson, Lawrence Blonde, Daniel Einhorn, George Grunberger, Yehuda Handelsman, Richard Hellman, Harold Lebovitz, Philip Levy, Victor L. Roberts, Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus: <i>ACE/AACE Diabetes Road Map Task Force</i>, Endocrine Practice, 2007, 13, 3, 260

    CrossRef

  62. 62
    Hermes Florez, Jennifer Marks, Geriatric Diabetes, 2007,

    CrossRef

  63. 63
    C Wysham, Type 1 Diabetes in Adults, 2007,

    CrossRef

  64. 64
    Anna Nogid, David Q. Pham, Adjunctive Therapy with Pramlintide in Patients with Type 1 or Type 2 Diabetes Mellitus, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006, 26, 11
  65. 65
    Liza Kirsty Phillips, Michael Horowitz, Amylin, Current Opinion in Endocrinology & Diabetes, 2006, 13, 2, 191

    CrossRef

  66. 66
    Francine Ratner Kaufman, Consequences of Weight Gain Associated With Insulin Therapy in Adolescents, The Endocrinologist, 2006, 16, 3, 155

    CrossRef

  67. 67
    George S Jeha, Rubina A Heptulla, Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations, Pediatric Diabetes, 2006, 7, 2
  68. 68
    Kerri L. Palamara, Harriette R. Mogul, Stephen J. Peterson, William H. Frishman, Obesity, Cardiology in Review, 2006, 14, 5, 238

    CrossRef

  69. 69
    John Pullman, Tamara Darsow, Juan P Frias, Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes, Vascular Health and Risk Management, 2006, 2, 3, 203

    CrossRef

  70. 70
    S. V. EDELMAN, T. DARSOW, J. P. FRIAS, Pramlintide in the treatment of diabetes, International Journal of Clinical Practice, 2006, 60, 12
  71. 71
    Laura L. Want, Robert E. Ratner, Pramlintide: A new tool in diabetes management, Current Diabetes Reports, 2006, 6, 5, 344

    CrossRef

  72. 72
    Harold E. Lebovitz, THERAPEUTIC OPTIONS IN DEVELOPMENT FOR MANAGEMENT OF DIABETES: PHARMACOLOGIC AGENTS AND NEW TECHNOLOGIES, Endocrine Practice, 2006, 12, s1, 142

    CrossRef

  73. 73
    Current literature in diabetes, Diabetes/Metabolism Research and Reviews, 2005, 21, 5
  74. 74
    Andrew A. Young, Carolyn Jodka, Richard Pittner, David Parkes, Bronislava R. Gedulin, Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats, Regulatory Peptides, 2005, 130, 1-2, 19

    CrossRef

  75. 75
    Marcelo LG Correia, William G Haynes, Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines, Expert Opinion on Emerging Drugs, 2005, 10, 3, 643

    CrossRef

  76. 76
    Gina J. Ryan, Lynetta J. Jobe, Rhonda Martin, Pramlintide in the treatment of type 1 and type 2 diabetes mellitus, Clinical Therapeutics, 2005, 27, 10, 1500

    CrossRef

  77. 77
    Andrew Young, Amylin: Physiology and Pharmacology, 2005,

    CrossRef

  78. 78
    Andisheh Abedini, Daniel P. Raleigh, Islet Amyloid Polypeptide,